Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax Vaccines
New findings from Harvard University in the area of anthrax vaccines described
March 19th, 2008
Data detailed in 'Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates' have been presented. "Protective antigen (PA) is a central component of anthrax toxin and a major antigen in anthrax vaccines. However, the use of native PA as a vaccine is not optimal," researchers in the United States report. "If administered to people who have been freshly exposed to anthrax, PA may actually aid in anthrax toxin formation and thus may pose a serious safety concern for postexposure vaccination applications. A non-functional PA mutant may be a much safer alternative. To identify an improved anthrax vaccine antigen, we examined...
Source: Vaccine Weekly (2008-03-19)
|
